Alembic gets USFDA nod for generic drug

Alembic Pharmaceuticals on Friday said it has received approval from the US health regulator to market a generic medication for the prevention of heart attack and stroke. The company has received final approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Ticagrelor Tablets, 90 mg and tentative approval for Ticagrelor Tablets, 60 mg, Alembic Pharma said in a statement.

The company’s approved ANDA is therapeutically equivalent to AstraZeneca Pharmaceuticals’s Brilinta Tablets, 60 mg and 90 mg, it added.

Ticagrelor tablets are indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome.

For Ticagrelor Tablets, 90 mg, Alembic was one of the first ANDA applicants to submit a substantially complete ANDA with a paragraph IV certification, the drug firm said.

According to IQVIA, Ticagrelor Tablets (90 mg) have an estimated market size of USD 1,062 million for twelve months ending March 2025.

Ticagrelor Tablets, 60 mg have an estimated market size of USD 242 million for twelve months ending March 2025.

Alembic shares were trading 0.03 per cent down at Rs 876.10 apiece on BSE.

Related Posts

Annovis Bio receives US patent covering new crystalline form of buntanetap

Annovis Bio, Inc. (Annovis), a phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), announced that…

Bengaluru: Medical devices worth ₹13.79 lakh seized in enforcement drive

The enforcement wing of Karnataka’s Food Safety and Drugs Control Department has seized medical devices and consumables worth ₹13.79 lakh from two establishments in Bengaluru’s Cottonpet area for alleged violations…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Annovis Bio receives US patent covering new crystalline form of buntanetap

Annovis Bio receives US patent covering new crystalline form of buntanetap

Bengaluru: Medical devices worth ₹13.79 lakh seized in enforcement drive

Bengaluru: Medical devices worth ₹13.79 lakh seized in enforcement drive

Yashoda Medicity Unveils T-Shirts & Finisher Medals ahead of Yashoda Half Marathon 4.0

Yashoda Medicity Unveils T-Shirts & Finisher Medals ahead of Yashoda Half Marathon 4.0

PharmEasy sees need for early prevention and regular screening to stall risk of diabetes

PharmEasy sees need for early prevention and regular screening to stall risk of diabetes

Saudi pharma company seeks Indian manufacturers for product registration, commercialisation in Saudi Arabia

Saudi pharma company seeks Indian manufacturers for product registration, commercialisation in Saudi Arabia

From ‘Kidney Care’ to ‘Liver Detox’, Uttar Pradesh bans misleading supplement labels

From ‘Kidney Care’ to ‘Liver Detox’, Uttar Pradesh bans misleading supplement labels